In the era of precision medicine, we should select the most suitable treatment strategy by predicting the sensitivity of HER2-positive breast cancer patients to neoadjuvant therapy, aiming to achieve the best therapeutic outcomes while minimizing side effects. The gene discussed is ERBB2; the disease is breast carcinoma.